Biotech & Health Tech
Trump’s drug pricing deals force tough choices on launches
Companies that committed to President Donald Trump’s drug pricing policy now face difficult decisions when launching new medicines. The “most favored nation” (MFN) pricing policy seeks to tie US drug prices to those charged in ...
Companies that committed to President Donald Trump’s drug pricing policy now face difficult decisions when launching new medicines. The “most favored nation” (MFN) pricing policy seeks to tie US drug prices to those charged in ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗